Φορτώνει......
Targeting RRM2 and Mutant BRAF is a Novel Combinatorial Strategy for Melanoma
The majority of melanoma patients harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) is relatively short-lived with progression free survival of only 6–7 months. Previously, we reported high expression of ribonucleo...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Mol Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5025362/ https://ncbi.nlm.nih.gov/pubmed/27297629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-16-0099 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|